WHAT IS CLAIMED IS:

1. A compound of the formula:

$$\begin{array}{c}
R^2 \\
N \\
(R^4)_p
\end{array}$$

$$\begin{array}{c}
R^3
\end{array}$$

3 or a pharmaceutically acceptable salt thereof,

4 wherein

1

2

13

15

16

1

2

5 n is 0, 1 or 2;

6 p is 1 or 2;

 R^1 is aryl or heteroaryl;

8 R² is a heterocyclyl;

9 R³ is hydrogen, alkyl, or -C(=O)-R⁵, where R⁵ is alkyl, alkoxy, aryl, or aryloxy;

10 and

each R⁴ is independently hydrogen, hydroxy, cyano, alkyl, alkoxy, thioalkyl, alkoxy, thioalkyl, alkylthio, halo, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl,

alkylcarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, amino,

alkylamino, dialkylamino, alkyl(aryl)amino, alkylaminocarbonyl,

alkylcarbonylamino, alkylcarbonyl(alkylamino), alkylaminosulfonyl,

alkylsulfonylamino or methylenedioxy.

- 2. The compound according to Claim 1, wherein p is 1 and R⁴ is located at the 6-position of the indole ring system.
- 1 3. The compound according to Claim 1, wherein R² is optionally substituted 2 piperazin-1-yl or optionally substituted piperidin-4-yl.
- 1 4. The compound according to Claim 3, wherein R² is piperazin-1-yl, 4-2 methylpiperazin-1-yl, 3,5-dimethylpiperazin-1-yl, N-methyl piperidin-4-yl or piperidin-4-yl.

The compound according to Claim 4, wherein R² is 4-methylpiperazin-1-1 5. 2 yl. The compound according to Claim 3, wherein R¹ is optionally substituted 1 6. 2 phenyl or optionally substituted thienyl. The compound according to Claim 6, wherein R¹ is thien-2-yl or phenyl 1 7. 2 which is optionally substituted with alkyl, halo, or haloalkyl. The compound according to Claim 7, wherein R¹ is phenyl, 2,3-1 8. dichlorophenyl, 2-fluorophenyl, 2-methylphenyl, 2-trifluoromethylphenyl, 3-bromophenyl, or 2 3 thien-2-yl. 9. 1 The compound according to Claim 6, wherein n is 2. The compound according to Claim 9, wherein R³ is hydrogen, methyl or – 1 10. $C(=O)-R^5$, where R^5 is alkoxy. 2 The compound according to Claim 1, wherein R¹ is thienvl or phenvl 1 11. 2 which is optionally mono- or di-substituted independently with alkyl, halo, haloalkyl. The compound according to Claim 11, wherein R¹ is phenyl, 2,3-12. 1 dichlorophenyl, 2-fluorophenyl, 2-methylphenyl, 2-trifluoromethylphenyl, 3-bromophenyl, or 2 3 thien-2-yl. The compound according to Claim 11, wherein n is 2. 1 13. The compound according to Claim 13, wherein R² is optionally substituted 1 14. 2 piperazin-1-yl or optionally substituted piperidin-4-yl. The compound according to Claim 14, wherein R² is piperazin-1-yl, 4-1 15. methylpiperazin-1-yl, 3,5-dimethylpiperazin-1-yl, N-methyl piperidin-4-yl or piperidin-4-yl. 2

HALLR6 #121217v3 31 R0142B-REG

1

2

16. The comp $-C(=O)-R^5$, where R^5 is alkoxy.

The compound according to Claim 15, wherein R³ is hydrogen, methyl or

- 1 The compound according to Claim 1, wherein n is 2.
- 1 18. The compound according to Claim 17, wherein R¹ is thienyl or phenyl
- which is optionally mono- or di-substituted independently alkyl, halo, haloalkyl.
- 1 19. The compound according to Claim 18, wherein R² is optionally substituted
- 2 piperazin-1-yl or optionally substituted piperidin-4-yl.
- 1 20. The compound according to Claim 19, wherein R³ is hydrogen, methyl or
- 2 $-C(=O)-R^5$, where R^5 is alkoxy.
 - 21. A method for producing a 2-substituted indole of the formula:

$$R^2$$

$$N$$

$$R^3$$

$$R^3$$

2

1

4 wherein

- 5 n is 0, 1, or 2;
- 6 p is 1 or 2;
- R^1 is aryl or heteroaryl;
- R² is a heterocycle optionally protected with a protecting group:
- R^3 is hydrogen, alkyl, or $-C(=O)-R^5$, where R^5 is alkyl, alkoxy, aryl, or aryloxy;
- 10 and
- each R⁴ is independently hydrogen, hydroxy, cyano, alkyl, alkoxy, thioalkyl,
- 12 alkylthio, halo, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl,
- alkylcarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, amino,
- 14 alkylamino, dialkylamino, alkyl(aryl)amino, alkylaminocarbonyl,
- alkylcarbonylamino, alkylcarbonyl(alkylamino), alkylaminosulfonyl,
- alkylsulfonylamino or methylenedioxy;
- said method comprising contacting a substituted indole of the formula:

- 18
- 19 wherein R^{3} is alkyl or $-C(=0)-R^{5}$,
- 20 (i) with a base to produce a deprotonated indole; and
- 21 (ii) contacting the deprotonated indole with a sulfonylating agent of the formula:
- Y-SO₂-R¹, where Y is halide, or a disulfide agent of the formula: R¹-S-S-R¹ to produce 2-
- 23 substituted indole of the formula:

$$R^2$$

$$N$$

$$S(O)_n - R^1$$

$$R^{3'}$$

- 24
- 25 (iii) optionally oxidizing the sulfur with an oxidizing agent; and
- 26 (iv) optionally removing the protecting group to produce the 2-substituted indole.
- 1 22. The method of Claim 21, wherein Y is fluorine.
- 1 23. A composition comprising:
- 2 (a) a therapeutically effective amount of a compound of Claim 1; and
- 3 (b) a pharmaceutically acceptable carrier.
- 1 24. A method for treating a CNS disease state in a subject, said method
- 2 comprising administering to said subject a therapeutically effective amount of a compound of
- 3 Claim 1.
- 1 25. The method of Claim 24, wherein the disease state comprises psychoses,
- 2 schizophrenia, manic depressions, neurological disorders, memory disorders, attention deficit
- disorder, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and
- 4 Huntington's disease.
- 1 26. A method for treating a disorder of the gastrointestinal tract in a subject,
- 2 said method comprising administering to said subject a therapeutically effective amount of a
- 3 compound of Claim 1.

- 1 27. A method for treating obesity in a subject, said method comprising
- 2 administering to said subject a therapeutically effective amount of a compound of Claim 1.

3